Morgan Stanley
XLO icon

Morgan Stanley’s Xilio Therapeutics XLO Stock Holding History

Morgan Stanley’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Sell
57,493
-2,496
-4% -$20.4K ﹤0.01% 5502
2025
Q4 		$538K Sell
59,989
-8,719
-13% -$91.6K ﹤0.01% 5472
2025
Q3 		$811K Sell
68,708
-34,458
-33% -$345K ﹤0.01% 5269
2025
Q2 		$982K Buy
103,166
+20,606
+25% +$218K ﹤0.01% 5109
2025
Q1 		$837K Buy
82,560
+11,034
+15% +$139K ﹤0.01% 5090
2024
Q4 		$956K Sell
71,526
-37,196
-34% -$512K ﹤0.01% 5118
2024
Q3 		$1.2M Buy
108,722
+29,241
+37% +$359K ﹤0.01% 4941
2024
Q2 		$1.05M Buy
79,481
+63,631
+401% +$996K ﹤0.01% 4929
2024
Q1 		$240K Sell
15,850
-2,331
-13% -$22.5K ﹤0.01% 5668
2023
Q4 		$140K Buy
18,181
+16,305
+869% +$322K ﹤0.01% 6059
2023
Q3 		$55.4K Sell
1,876
-54
-3% -$2.01K ﹤0.01% 6124
2023
Q2 		$70.8K Sell
1,930
-251
-12% -$10.7K ﹤0.01% 6082
2023
Q1 		$96.8K Buy
2,181
+352
+19% +$15.5K ﹤0.01% 6015
2022
Q4 		$68.9K Buy
1,829
+1,340
+274% +$45.2K ﹤0.01% 6145
2022
Q3 		$20K Sell
489
-14
-3% -$544 ﹤0.01% 6800
2022
Q2 		$20K Buy
503
+353
+235% +$18.7K ﹤0.01% 6993
2022
Q1 		$14K Buy
150
+76
+103% +$12K ﹤0.01% 7289
2021
Q4 		$17K Buy
+74
New +$17.6K ﹤0.01% 7283

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Morgan Stanley's XLO Position: Q1 2026 in Review

Morgan Stanley reduced its Xilio Therapeutics (XLO) stake by 4.2% in Q1 2026, selling an estimated $20.4K and leaving 57,493 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #5502.

Morgan Stanley first reported a position in XLO in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.2M in Q3 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Morgan Stanley held 57,493 shares of Xilio Therapeutics worth $484K as of Q1 2026.
  • Morgan Stanley sold 2,496 Xilio Therapeutics shares in Q1 2026, an estimated $20.4K.
  • Xilio Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5502 holding.
  • Morgan Stanley first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Morgan Stanley's Xilio Therapeutics position peaked at $1.2M in Q3 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.